Gen-Wealth Partners
NTLA icon

Gen-Wealth Partners’s Intellia Therapeutics NTLA Stock Holding History

Gen-Wealth Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$991K Buy
82,177
+20,834
+34% +$261K 0.28% 85
2026
Q2 		$1.04M Buy
61,343
+14,167
+30% +$198K 0.29% 78
2026
Q1 		$605K Buy
47,176
+13,861
+42% +$177K 0.19% 110
2025
Q4 		$299K Buy
33,315
+28,012
+528% +$386K 0.1% 218
2025
Q3 		$91.6K Buy
5,303
+5,262
+12,834% +$64.8K 0.03% 330
2025
Q2 		$385 Hold
41
– – ﹤0.01% 618
2025
Q1 		$292 Hold
41
– – ﹤0.01% 599
2024
Q4 		$478 Hold
41
– – ﹤0.01% 622
2024
Q3 		$588 Hold
41
– – ﹤0.01% 631
2024
Q2 		$918 Hold
41
– – ﹤0.01% 601
2024
Q1 		$1.13K Buy
+41
New +$1.14K ﹤0.01% 580

Other funds holding NTLA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Gen-Wealth Partners's NTLA Position: Q3 2026 in Review

Gen-Wealth Partners increased its Intellia Therapeutics (NTLA) stake by 34% in Q3 2026, buying an estimated $261K and bringing the position to 82,177 shares worth $991K. The position accounts for 0.28% of the portfolio, ranked #85.

Gen-Wealth Partners first reported a position in NTLA in Q1 2024 and has held it in 11 quarters since. The position peaked at $1.04M in Q2 2026. 239 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • Gen-Wealth Partners held 82,177 shares of Intellia Therapeutics worth $991K as of Q3 2026.
  • Gen-Wealth Partners bought 20,834 Intellia Therapeutics shares in Q3 2026, an estimated $261K.
  • Intellia Therapeutics made up 0.28% of Gen-Wealth Partners's portfolio in Q3 2026, its #85 holding.
  • Gen-Wealth Partners first reported a position in Intellia Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • Gen-Wealth Partners's Intellia Therapeutics position peaked at $1.04M in Q2 2026.
  • 239 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Gen-Wealth Partners's 13F filing for Q3 2026, filed 4 Nov 2026.